Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Mol Med Rep 20(1):701708 Luo Y, Yang P, Li Z, Luo Y, Shen J, Li R, Zheng H, Liang Y, Xia N (2019) Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways
No FDA-approved dose exists: All BPC-157 protocols at Perfect B are individualized at the APRN intake before any medication is prescribed
CASGEVY makes history as FDA approves first CRISPR/Cas9 genome edited therapy
In propensity-matched analyses, semaglutide treatment was associated with lower rates of several cardiovascular outcomes than treatment with metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors
Johnson DW, Jones GR, Mathew TH, et al